Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis

Ижил төстэй зүйлс

• Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
  -н: Helliwell, P, зэрэг
  Хэвлэсэн: (2018)
• Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
  -н: Philip Helliwell, зэрэг
  Хэвлэсэн: (2018-10-01)
• Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
  -н: Nash, P, зэрэг
  Хэвлэсэн: (2018)
• Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
  -н: Peter Nash, зэрэг
  Хэвлэсэн: (2018-11-01)
• Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
  -н: Coates, L, зэрэг
  Хэвлэсэн: (2021)